Abstracts Archive - Page 609 of 2607 - ACR Meeting Abstracts

Abstract Number: 1895 • ACR Convergence 2022
Association Between Synovial Tissue Metabolomic Profile and Pain in Patients with Knee Osteoarthritis
Jessica Murillo Saich¹, Roxana Coras², Robert Meyer³, Nancy Lane⁴ and Monica Guma⁵, ¹University of California San Diego, La Jolla, CA, ²University of California San Diego, San Diego, CA, ³San Diego VA Healthcare Service, San Diego, CA, ⁴University of California Davis, Hillsborough, CA, ⁵UCSD, La Jolla, CA
Background/Purpose: Increasing evidence indicates that osteoarthritis (OA) progression is mediated by low-grade synovial inflammation (synovitis) that contributes to joint pain and stiffness, especially in knee…
Abstract Number: 1885 • ACR Convergence 2022
Histopathological Patterns of Muscle Involvement and Clinical Correlations in a Retrospective Cohort of Scleroderma Patients
Noemie Le Gouellec¹, Louai Zaidan², Eric Hachulla³, Nicolas Dognon³, Robin Dhote⁴, Sebastien Riviere⁵, Yurdagul Uzunhan⁴, Luc Mouthon⁶ and Jerome Authier⁷, ¹CH Valenciennes, Valenciennes, France, ²CHU Henri Mondor, Creteil, France, ³University of Lille, LILLE, France, ⁴Hopital Avicenne - Paris University, Bobigny, France, ⁵Hopital Saint Antoine - Paris University, Paris, France, ⁶Hopital Cochin - Paris University, Paris, France, ⁷Paris Est - Creteil University, Creteil, France
Background/Purpose: Muscle involvement in systemic sclerosis (SSc) has been shown to be heterogeneous. Histopathological pattern seems to be associated with prognosis, but studies evaluating the…
Abstract Number: 1893 • ACR Convergence 2022
Antihistamine Use and Structural Progression of Knee OA: A Post-Hoc Analysis of Two Phase 3 Clinical Trials
Asger Bihlet¹, Claire Miller¹, Inger Byrjalsen¹, Morten Karsdal², Jeppe Andersen¹, Tharaknath Rao³ and Matthew Baker⁴, ¹NBCD, Copenhagen, Denmark, ²Nordic Bioscience, Herlev, Denmark, ³Mobility Bio, San Diego, CA, ⁴Mobility Bio, San Diego
Background/Purpose: Prior studies indicate that mast cells are involved in chronic inflammation and that their activity in the synovium may contribute to structural progression of…
Abstract Number: 1906 • ACR Convergence 2022
Bile Acid Profile Is Associated to Synovitis in Knee Osteoarthritis
Roxana Coras¹, Jessica Murillo Saich², Michal Hose Sanchez³, Anne Quan³, Emily Gentry¹, Pieter Dorrestein¹, Nancy Lane⁴ and Monica Guma⁵, ¹University of California San Diego, San Diego, CA, ²University of California San Diego, La Jolla, CA, ³VA San Diego Healthcare System, San Diego, CA, ⁴University of California Davis, Hillsborough, CA, ⁵Division of Rheumatology, Allergy, and Immunology, Department of Medicine, University of California San Diego, La Jolla, CA
Background/Purpose: Increasing evidence indicates that low grade systemic and local inflammation contributes to osteoarthritis (OA) progression. Bioactive lipid mediators are signaling molecules involved in inflammatory…
Abstract Number: 1900 • ACR Convergence 2022
CoLchicine for Treatment of OsteoArthritis of the Knee (CLOAK)-A Double-blind, Placebo-controlled Trial
Jonathan Samuels¹, Michael Pillinger², Michael Toprover³, Svetlana Krasnokutsky Samuels⁴, Apoorva Patil⁵, Fernando Bomfim⁶, Renata La Rocca Vieira⁶, David Wei⁵, Sydney Catron⁵, Maryfe coronel⁵, Annie Kim⁵ and Sarah Moussavi⁵, ¹NYU Langone, Rye Brook, NY, ²NYU Grossman School of Medicine, New York, NY, ³Division of Rheumatology, New York University Grossman School of Medicine and Rheumatology Section, New York Harbor Health Care System, New York Campus of the U.S. Department of Veterans Affairs, New York, NY, ⁴Westmed, Rye Brook, NY, ⁵NYU Langone Health, New York, NY, ⁶NYU Langone, New York, NY
Background/Purpose: Knee osteoarthritis (OA) is an inflammatory disease, with a probable role for IL-1b. Calcium and urate crystals may promote OA by activating the NLRP3…
Abstract Number: 1902 • ACR Convergence 2022
Structural Severity in Knee Osteoarthritis Impacts Treatment Response: A Post Hoc Pooled Analysis of Lorecivivint Clinical Trials
Yusuf Yazici¹, Christopher Swearingen², Heli Ghandehari³, ismail simsek⁴, Sarah Kennedy⁵, Jeyanesh Tambiah⁶ and Timothy McAlindon⁷, ¹New York University School of Medicine, La Jolla, CA, ²Samumed LLC, San Diego, CA, ³Biosplice Therapeutics, Inc., San Diego, CA, ⁴Alpine Immunesciences, San Diego, CA, ⁵Biosplice Therapeutics, Inc, San Diego, CA, ⁶Biosplice Ther Inc., San Diego, CA, ⁷Tufts Medical Center, Arlington, MA
Background/Purpose: Osteoarthritis (OA) is a leading cause of disability globally, and its disease burden is expected to increase as risk factors such as aging and…
Abstract Number: 1898 • ACR Convergence 2022
Radiographic Osteoarthritis Progression Can Be Predicted via Pyrosequencing Analysis of Baseline Peripheral Blood
Chris Dunn¹, Cassandra Velasco², Leoni Schlupp³, Emmaline Prinz³, Vladislav Izda⁴, Liubov Arbeeva⁵, Yvonne Golightly⁶, Amanda Nelson⁶ and Matlock Jeffries³, ¹University of Oklahoma Health Sciences Center, Edmond, OK, ²University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Oklahoma Medical Research Foundation, New York, NY, ⁵University of North Carolina Chapel Hill, Chapel Hill, NC, ⁶UNC School of Medicine, Chapel Hill, NC
Background/Purpose: Knee osteoarthritis (OA) is a heterogeneous disease characterized by a variety of clinical and molecular phenotypes. However, we do not yet have robust biomarkers…
Abstract Number: 1909 • ACR Convergence 2022
Corticosteroids with or Without Hyaluronic Acid Injections in the Treatment of Trapeziometacarpal (TMC) Osteoarthritis : The Randomised Multicentre RHIZ’ART Trial Study Protocol
Grégoire Cormier¹, Amelie Denis², CHARLES LESKE³, Stephane Varin¹, Jerome Dimet⁴, Lucie Planche¹ and Benoit Le Goff⁵, ¹CHD Vendee, La Roche Sur Yon, France, ²CH Le Mans, Le Mans, France, ³Hospital, Cholet, France, ⁴CH Mont de Marsan, Mont de Marsan, France, ⁵CHU Nantes, Nantes, France
Background/Purpose: Trapeziometacarpal osteoarthritis is highly prevalent (affects 10 to 25% of people). Treatment modalities consist of non-pharmacological and pharmacological measures, including either corticosteroid or hyaluronic…
Abstract Number: 1911 • ACR Convergence 2022
Baseline Bone Curvature a Biomarker for the Prediction of Knee Osteoarthritis Cartilage Volume Loss at One-Year. Use of Machine Learning
Johanne Martel-Pelletier¹, Hossein Bonakdari¹, Jean-Pierre Pelletier¹ and François Abram², ¹Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montréal, QC, Canada, ²ArthroLab Inc., Montréal, QC, Canada
Background/Purpose: The hallmark of osteoarthritis is the loss of cartilage. At present, we cannot discriminate, early during the osteoarthritis process, patients for whom cartilage will…
Abstract Number: 1908 • ACR Convergence 2022
Should Osteoarthritis Patients with Pain Scores More Than 8/10 Be Analyzed Separately or Excluded from Clinical Trial Protocols, as 72% Screen Positive for Fibromyalgia And/or Depression on a Multidimensional Health Assessment Questionnaire (MDHAQ)?
Juan Schmukler¹, Kathryn Gibson², Tengfei Li³, Joel Block¹ and Theodore Pincus¹, ¹Rush University Medical Center, Chicago, IL, ²Liverpool Hospital, Sydney, Australia, ³Georgetown University, Washington, DC
Background/Purpose: Most osteoarthritis (OA) clinical trial protocols require a 0-10 pain visual numeric scale (VNS) or other quantitative pain score of 4/10 or more for…
Abstract Number: 1910 • ACR Convergence 2022
Evaluation of Dynamic Effects of Depressive Symptoms on Functional Outcomes in Knee Osteoarthritis
Rhea Mehta¹, Marc Hochberg², Michelle Shardell¹, Alice Ryan¹, Yu Dong¹, Brock Beamer¹, Jason Peer², Megan Schuler³, Joseph Gallo⁴, Elizabeth Stuart⁴ and Alan Rathbun¹, ¹University of Maryland, School of Medicine, Baltimore, MD, ²University of Maryland School of Medicine, Baltimore, MD, ³Rand Inc., Boston, MA, ⁴Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
Background/Purpose: Knee OA is a leading cause of functional decline, and psychiatric comorbidity is common, particularly major depression. Depressive symptoms decrease physical activity and exacerbate…
Abstract Number: 1407 • ACR Convergence 2022
Longitudinal Lipid Profile and NT-proBNP Changes from Pre-clinical to Established Rheumatoid Arthritis: A 12 Years Follow up Explorative Study
Reinder Raadsen¹, Laurette van Boheemen¹ and Michael Nurmohamed², ¹Reade Rheumatology Center, Amsterdam, Netherlands, ²Amsterdam University Medical Center, Kortenhoef, Netherlands
Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased risk for developing cardiovascular diseases (CVD). This is partly due to the systemic inflammation characteristic to…
Abstract Number: 1852 • ACR Convergence 2022
Clinical Efficacy and Safety of Guselkumab Maintenance Therapy in Patients with Moderately to Severely Active Crohn’s Disease: Week 48 Analyses from the Phase 2 GALAXI 1 Study
Silvio Danese¹, Remo Panaccione², David T. Rubin³, Bruce E. Sands⁴, Walter Reinisch⁵, Geert D’Haens⁶, Julián Panés⁷, Susana Gonzalez⁸, Kathleen Weisel⁸, Aparna Sahoo⁸, Mary Ellen Frustaci⁸, Zijiang Yang⁸, William J. Sandborn⁹, Anita Afzali¹⁰, Tadakazu Hisamatsu¹¹, Jane M. Andrews¹² and Brian G. Feagan¹³, ¹Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Milano, Italy, ²Inflammatory Bowel Disease Group, University of Calgary, Calgary, AB, Canada, ³University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL, ⁴Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA, Chicago, IL, ⁵Division of Gastroenterology & Hepatology, Medical University of Vienna, Vienna, Austria, ⁶Department of Gastroenterology, Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁷Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain, ⁸Immunology, Janssen Research & Development, LLC, Spring House, PA, ⁹Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA, La Jolla, ¹⁰Wexner Medical Center, The Ohio State University, Columbus, OH, ¹¹Department of Gastroenterology and Hepatology, Kyorin University, Tokyo, Japan, ¹²Department of Gastroenterology & Hepatology, Royal Adelaide Hospital & University of Adelaide, Adelaide, Australia, ¹³Western University and Senior Scientific Director, Alimentiv Inc (formerly Robarts Clinical Trials Inc), London, ON, Canada
Background/Purpose: GALAXI 1 is a Phase 2, double-blind, placebo (PBO)-controlled, multicenter study evaluating the efficacy/safety of guselkumab (GUS), a selective IL-23 p19 antagonist, in patients…
Abstract Number: 1802 • ACR Convergence 2022
The Utility of Dual-energy Computed Tomography in Gout Patients During Urate Lowering Therapy
Min Jung Kim¹, Mi Hyeon Kim², SE RIM CHOI², Youjin Jung², Ji In Jung², Ju Yeon Kim², Jee Won Chai³ and Kichul Shin⁴, ¹Seoul Metropolitan Government Boramae Medical center, Dongjak-gu, Seoul, Republic of Korea, ²Seoul National University Hospital, Seoul, Republic of Korea, ³Seoul Metropolitan Government–Seoul National University Boramae Medical Center, Seoul, Republic of Korea, ⁴Seoul Metropolitan Government- Seoul National University Boramae Medical Center, Seoul, Republic of Korea
Background/Purpose: To investigate whether monosodium urate (MSU) deposition measured by dual-energy computed tomography (DECT) could help predict acute flares after discontinuing colchicine prophylaxis in patients…
Abstract Number: 1658 • ACR Convergence 2022
Association Between Anti-Sjögren Syndrome/Scleroderma Autoantigen 1 (SSSCA1) Antibodies and Cancer in Systemic Sclerosis
Rachel Wallwork¹, Livia Casciola-Rosen¹ and Ami Shah², ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins Rheumatology, Baltimore, MD
Background/Purpose: We sought to examine the association between anti-Sjögren syndrome/scleroderma autoantigen 1 (SSSCA1) antibody and cancer in systemic sclerosis (SSc). We also describe the frequency…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].